Ann: VivaGel BV launched in Asia, page-11

Sensitive most likely because it reaches a milestone payment. Below is from the 03/05/2018 announcement.

"Mundipharma will register and launch VivaGel® BV as part of the popular BETADINE® range,
which is sold in more than 120 countries. BETADINE® has a market leading position in
Feminine Care and this licence enables Mundipharma to develop the consumer market for
VivaGel® BV in rapidly developing markets across Asia, the Middle East, Africa and Latin
America, where demand for trusted intimate health and hygiene products is growing.
Under the licence, Starpharma will receive returns via a revenue share on VivaGel® BV
sales. In addition, Starpharma is eligible to receive signing, regulatory and commercial
milestones totaling up to A$12.2 million (US$9.2 million) including a A$1.3 million
(US$1 million) upfront payment. The term of the agreement is 15 years and incorporates
commercial performance obligations, including minimum annual purchases by
Mundipharma. Other commercial terms of the agreement remain confidential"